Arming the immune system so it can recognize and attack cancer is now a proven strategy for success in fighting some forms of the disease, notably blood cancers. However, immunotherapy for solid tumors has proven to be elusive.
Checking your phone at the doctor’s office? Do not be surprised if you get an ad for a drug you can talk to your doctor about. Data-as-a-service provider Semcasting is using IP address targeting to serve messages to patients’ smartphones while they are waiting at appointments.
With every breath we take, we release thousands of organic compounds that can reveal the early activity of diseases hidden within the body. To put them to work, researchers at the University of Huddersfield in England hope to collect and screen those chemicals for signs linked to multiple sclerosis. The University’s Centre for Biomarker Research has begun a study that will analyze the breaths from people living with various stages of MS and compare them to samples from healthy volunteers.
Despite tough talk, President Donald Trump has watched U.S. drug prices climb since he took office. Now, Trump says he favors an executive order to address the problem — but his approach has some experts bewildered.
Looks like unloading surplus manufacturing sites to the cannabis industry is turning into a budding business for pharma. At the same time Novartis was negotiating a deal to sell a Colorado plant to a CBD producer, a former Pfizer site was leased to a to a medical marijuana supplier.
Abbott has launched its new point-of-care diabetes blood test that can provide hemoglobin A1c results in only three minutes, allowing clinicians to develop and start care plans within a patient’s single visit to a doctor’s office.
CA19-9, or sialyl-Lewis, is a sugar molecule that's present on many proteins and is often elevated in patients with pancreatitis and pancreatic cancer. Therefore it has been used for more than 30 years to assess disease burden. However, now a team of scientists at Cold Spring Harbor Laboratory (CSHL) have found that CA19-9 may, in fact, promote the development of these pancreatic diseases.
The FDA is polling the industry and the public for ideas on where the Agency should focus when it comes to addressing patient preferences for medical devices, to help build out its new list of priorities that could impact the structure of premarket clinical studies, risk-benefit assessments and post-market reviews.